Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP96 Vaccine in Liver Cancer
NCT04206254Phase 3Unknown
- Sponsor
- Cure & Sure Biotech
- Start
- Dec 2019
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
A Phase 3 trial of vitespen in liver cancer, sponsored by Cure & Sure Biotech. Status: unknown.
02
Drugs
vitespen
03
Conditions
liver cancer
Beyond the preview
Go deeper on NCT04206254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04206254.